EnerSys ENS
New risk paragraphs, branching off last year
Each branch is a paragraph in Risk Factors with nothing like it in the 10-K filed May 21, 2025. A box jumps to the paragraph as filed, below.
Paragraphs with nothing like them in last year's 10-K
1 paragraph in Risk Factors of the 10-K filed May 20, 2026 with nothing like it in the 10-K filed May 21, 2025. Quoted exactly. Paragraphs that were only edited are under 10-K change.
•On January 5, 2026, the OECD issued the Side-by-Side package (the “SbS Package”), which provides administrative guidance that modifies the application of the Pillar Two rules. The SbS Package includes simplifications and additional safe harbors intended to facilitate coordination between domestic and international tax regimes and the Pillar Two framework. If adopted by relevant jurisdictions, certain provisions of the SbS Package could result in U.S.-parented groups being exempt from the application of two of the three Pillar Two top-up taxes.
Paragraphs in the 10-Q filed Nov 12, 2026 that were not in the one before
New in the latest 10-Q
18 paragraphs in the 10-Q filed Nov 12, 2026 with nothing like them in the 10-Q filed Aug 12, 2026 (at least half the words must differ; new numbers alone do not count). Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.
Financial statements and notes
(1) On October 1, 2026, the Company terminated $ 25,000 of cross-currency fixed interest rate swap contracts, originally entered into on December 24, 2024, and a paid net settlement of $ 2,011 on October 5, 2026.
Read in the 10-Q
During the second quarter of fiscal 2027, the Company completed a strategic review of its lithium battery manufacturing initiative and approved a revised strategy that significantly changed the scope of its previously announced lithium-ion cell manufacturing initiative and refocused the Greenville facility on aerospace, defense, and other specialized applications requiring a Foreign Entity of Concern compliant supply chain and a different cell format. As a result of this strategic realignment, the Company is working to transition away from its technology relationship with Verkor, which had previously been established to support the Company's originally planned lithium-ion cell manufacturing operations. The Company recorded charges of $ 13,476, consisting primarily of the write-off of deferred assets and other amounts that are no longer expected to provide future economic benefit, as well as estimated costs to transition away from the technology relationship with Verkor. As this transition is finalized, the precise scope, timing and time period at issue and the actual costs remain uncertain and, accordingly, the Company’s estimates may change from time to time, and actual losses could vary, with any resulting adjustments being recognized in the period incurred.
Read in the 10-Q
During the six months of fiscal 2027, the Company granted to management and other key employees 152,050 restricted stock units that vest ratably over four years from the date of grant and 37,537 PSUs that cliff vest three years from the date of the grant.
Read in the 10-Q
On October 27, 2026, The Company, entered into an Agreement and Plan of Merger (the “Merger Agreement”) with EnerSys Mergersub Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger Sub”), and Ultralife Corporation, a Delaware corporation (“Ultralife”).
Read in the 10-Q
The Merger Agreement provides for the acquisition of Ultralife by the Company in a two-step transaction, consisting of a tender offer followed by a subsequent merger of Merger Sub with and into Ultralife (the “Merger”). On October 28, 2026, pursuant to the Merger Agreement, Merger Sub commenced a tender offer (the “Offer”) to purchase all of the outstanding shares of Ultralife common stock, par value $ 0.10 per share (the “Shares”), for $ 16.00 per Share (the “Offer Price”), net to the seller in cash, without interest and subject to any required withholding of taxes. Following consummation of the Offer, the Merger will be effected under Section 251(h) of the Delaware General Corporation Law, as amended (the “DGCL”), without a meeting or vote of Ultralife’s stockholders, with Ultralife surviving the Merger as a wholly owned subsidiary of the Company. The transaction is subject to customary closing conditions, including the tender of at least a majority of the outstanding shares of Ultralife’s common stock and receipt of applicable regulatory approvals, and is expected to close in the first quarter of calendar year 2027. We expect to fund the transaction with cash on hand. Because the Merger Agreement was executed subsequent to the balance sheet date, no amounts related to the pending acquisition have been recognized in these condensed consolidated financial statements. As of the date these financial statements were issued, the acquisition had not been completed, and we are continuing to evaluate the accounting and disclosure effects of the transaction, including the related purchase accounting, and therefore cannot yet estimate all of the financial statement effects of the pending acquisition.
Read in the 10-Q
Show the other 13
• risks related to the proposed acquisition of Ultralife Corporation, a Delaware corporation (“Ultralife”);
Read in the 10-Q
Inflation in North America, China and EMEA remains a challenge, with recent geopolitical developments and volatility in energy prices contributing to inflationary pressures. Central banks continue to balance inflation concerns with economic growth, resulting in elevated interest rates that may affect economic activity and customer spending. Policy actions in China continue to support domestic consumption and economic growth; however, China's economy continues to face challenges from weak domestic demand, a prolonged weak real estate market and global trade tensions.
Read in the 10-Q
material costs. Foreign currency exchange rates have remained volatile amid changes in interest rates, trade policies and geopolitical conditions.
Read in the 10-Q
On October 27, 2026, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with EnerSys Mergersub Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger Sub”), and Ultralife. Under the terms of the Merger Agreement, the Company, through a subsidiary, will commence a tender offer to acquire all of the outstanding shares of Ultralife common stock at a price of $16.00 per share in cash at closing, representing a total enterprise value of approximately $320 million. The transaction is subject to customary closing conditions, including the tender of at least a majority of the outstanding shares of Ultralife’s common stock and receipt of applicable regulatory approvals, and is expected to close in the first quarter of calendar year 2027. If the proposed acquisition is consummated, we expect to fund the transaction with cash on hand, which would reduce our cash and cash equivalents balance.
Read in the 10-Q
During the second quarter of fiscal 2027, the Company completed a strategic review of its lithium battery manufacturing initiative and approved a revised strategy that significantly changed the scope of its previously announced lithium-ion cell manufacturing initiative and refocused the Greenville facility on aerospace, defense, and other specialized applications requiring a Foreign Entity of Concern compliant supply chain and a different cell format. As a result of this strategic realignment, the Company is working to transition away from its technology relationship with Verkor, which had previously been established to support the Company's originally planned lithium-ion cell manufacturing operations. The Company recorded charges of $13.5 million, consisting primarily of the write-off of deferred assets and other amounts that are no longer expected to provide future economic benefit, as well as estimated costs to transition away from the technology relationship with Verkor. As this transition is finalized, the precise scope, timing and time period at issue and the actual costs remain uncertain and, accordingly, the Company’s estimates may change from time to time, and actual losses could vary, with any resulting adjustments being recognized in the period incurred.
Read in the 10-Q
On March 25, 2026, the Company announced a plan to close its facility in Tijuana, Mexico, which focused on manufacturing lead acid batteries. Management determined that the closure was appropriate as part of its efforts to optimize its cost structure,
Read in the 10-Q
2026. The decrease in the quarter and six months was driven by unfavorable price/mix as customers delay purchases of higher margin product categories in anticipation of upcoming new product releases, and lost leverage from lower sales
Read in the 10-Q
Six Months Ended October 4, 2026 Six Months Ended September 28, 2025 Increase (Decrease)
Read in the 10-Q
Consolidated Condensed Financial Statements included in this Quarterly Report on Form 10-Q for a detailed description of our debt.
Read in the 10-Q
Risk Factors
We may be unable to successfully complete our acquisition of Ultralife, which could adversely affect our business and financial condition.
Read in the 10-Q
Our entry into the Merger Agreement with Ultralife represents several risks. The acquisition of Ultralife is subject to the satisfaction of a number of other conditions beyond the parties’ control that may prevent, delay or otherwise materially adversely affect the completion of the transaction. Completion of the transaction remains subject to the tender of at least a majority of Ultralife’s outstanding shares and the satisfaction of other customary closing conditions, and there can be no assurance that the acquisition will be completed on the expected terms, in the expected timeframe or at all. In addition, our realization of the value from the pending acquisition of Ultralife relies on successful integration and continued operations. We may not be able to integrate Ultralife’s business successfully into our existing business, realize the anticipated benefits of the pending acquisition, or retain key employees in connection with the pending acquisition, which could adversely affect our business and financial condition. Further, our ongoing business may be disrupted, and our management’s attention may be diverted by the pending Ultralife acquisition, including due to transition and/or integration activities following the closing of the acquisition. Securities class action lawsuits and derivative lawsuits are often brought against public companies that have entered into acquisition, merger or other business combination agreements. Even if such a lawsuit is without merit, defending against these claims can result in substantial costs and divert management time and resources.
Read in the 10-Q
Our investors should consider the risks set forth in Part I, Item 1A, Risk Factors, of our Annual Report that could affect us and our business. Although we have tried to discuss key factors, our investors need to be aware that other risks may prove to be important in the future. New risks may emerge at any time, and we cannot predict such risks or estimate the extent to which they may affect our financial performance. Investors should consider carefully the discussion of risks and the other information included or incorporated by reference in this Quarterly Report, including “Forward-Looking Statements,” which are included in Part I, Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Read in the 10-Q
Item 6
Number ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── 3.1 Fifth Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to Amendment No. 3 to the Company’s Registration Statement on Form S-1 (File No. 333-115553) filed on July 13, 2004). 3.2 Fifth Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q for the period ended December 29, 2024 (File No. 001-32253) filed on February 5, 2025). 31.1 Certification of Principal Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) Under the Securities Exchange Act of 1934 (filed herewith). 31.2 Certification of Principal Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) Under the Securities Exchange Act of 1934 (filed herewith). 32.1 Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith). 101. INS XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document. 101. SCH XBRL Taxonomy Extension Schema Document 101. CAL XBRL Taxonomy Extension Calculation Linkbase Document 101. DEF XBRL Taxonomy Extension Definition Linkbase Document 101. LAB XBRL Taxonomy Extension Label Linkbase Document 101. PRE XBRL Taxonomy Extension Presentation Linkbase Document
Read in the 10-Q
The 10-Q's risk factors against the 10-K
Item 1A of the 10-Q filed Nov 12, 2026 against Item 1A of the 10-K filed May 20, 2026.
A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed.
Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed,
Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal
(cut words struck through, new words highlighted).
Text on the page, not a score; each links to the filing at sec.gov.
What the 10-Q itself says about its risk factors:In addition to the other information set forth in this Form 10-Q and the risk factors set forth below, you should carefully consider the factors discussed in Part I, Item 1A. Risk Factors in our 2026 Annual Report and our Quarterly Report on Form 10-Q for the period ended July 5, 2026, which could materially affect our business, financial condition or future results.
Read in the 10-Q
Show the other 1
Phrases used for the first time
Two-word phrases in Risk Factors of the 10-K filed May 20, 2026 that are in none of the 1 earlier 10-Ks stored, back to May 21, 2025
Where each one is used
- sbs package: •On January 5, 2026, the OECD issued the Side-by-Side package (the “SbS Package”), which provides administrative guidance that modifies the application of the Pillar Two rules. The SbS Package includes simplifications and additional safe harbors intended to facilitate coordination between domestic and international...
Used at least twice, small words left out. Counted, not picked: a phrase can be new because the company renamed something.
Sources
Item 1A of each 10-K and 10-Q on EDGAR, quoted exactly. Each paragraph links to the filing at sec.gov.
Also
10-K change: what was reworded or cut, section by section.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ENS/export.csv") into a cell.